Literature DB >> 17888982

Cardioplegia and diazoxide modulate STAT3 activation and DNA binding.

Yng-Ju Hsieh1, Hidetaka Wakiyama, Sidney Levitsky, James D McCully.   

Abstract

BACKGROUND: Previously, we have shown that magnesium supplemented potassium (DSA) cardioplegia and DSA containing diazoxide (DSA+DZX) significantly decrease apoptosis after ischemia. The mechanism for this enhanced cardioprotection was unknown, but we believed that alterations in signal transducers and activators of transcription (STATs) may play a role. To investigate this hypothesis, we examined the effects of DSA and DSA+DZX cardioplegia on STAT1/3 phosphorylation and DNA binding in the in situ blood perfused pig heart model.
METHODS: Pigs (32 to 42 kg) undergoing total cardiopulmonary bypass underwent left anterior descending coronary artery occlusion for 30 minutes. The aorta was crossclamped and DSA (n = 6) or DSA+DZX (n = 6) cardioplegia was administered, followed by 30 minutes of global ischemia and 120 minutes of reperfusion. Control hearts (n = 3) received cardiopulmonary bypass and sham reperfusion only. Tissue samples from regional and global ischemia zones were harvested and used for Western blot and electrophoretic mobility shift assay.
RESULTS: Regional and global ischemia significantly increase proapoptotic STAT1 tyrosine phosphorylation. This increase is significantly greater in the regional as compared with the global ischemia zone. Tyrosine phosphorylation of antiapoptotic STAT3 is increased in the global ischemic zone but is significantly decreased in the regional ischemic zone and is associated with increased apoptosis. The DSA+DZX significantly increases tyrosine phosphorylation of antiapoptotic STAT3 and DNA binding in the regional ischemia zone and significantly decreases apoptosis.
CONCLUSIONS: The addition of diazoxide to DSA cardioplegia significantly decreases apoptosis by significantly increasing tyrosine phosphorylation of STAT3 and its DNA binding and represents an additional modality for enhancing myocardial protection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888982      PMCID: PMC3671580          DOI: 10.1016/j.athoracsur.2007.05.014

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  24 in total

Review 1.  The basic biology of apoptosis and its implications for cardiac function and viability.

Authors:  Guro Valen
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

Review 2.  Activated STAT-1 pathway in the myocardium as a novel therapeutic target in ischaemia/reperfusion injury.

Authors:  Anastasis Stephanou
Journal:  Eur Cytokine Netw       Date:  2002 Oct-Dec       Impact factor: 2.737

3.  Inhibition of RNA transcription modulates magnesium-supplemented potassium cardioplegia protection.

Authors:  H Matsuda; S Levitsky; J D McCully
Journal:  Ann Thorac Surg       Date:  2000-12       Impact factor: 4.330

4.  Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha 2-macroglobulin promoter.

Authors:  J Y Yoo; W Wang; S Desiderio; D Nathans
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

5.  JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion.

Authors:  E Mascareno; M El-Shafei; N Maulik; M Sato; Y Guo; D K Das; M A Siddiqui
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

Review 6.  Serine phosphorylation of STATs.

Authors:  T Decker; P Kovarik
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

7.  How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene.

Authors:  M Chatterjee-Kishore; K L Wright; J P Ting; G R Stark
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

Review 8.  Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury.

Authors:  Roberto Bolli; Buddhadeb Dawn; Yu-Ting Xuan
Journal:  Trends Cardiovasc Med       Date:  2003-02       Impact factor: 6.677

9.  Role of STAT3 in ischemic preconditioning.

Authors:  R Hattori; N Maulik; H Otani; L Zhu; G Cordis; R M Engelman; M A Siddiqui; D K Das
Journal:  J Mol Cell Cardiol       Date:  2001-11       Impact factor: 5.000

10.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.

Authors:  Z Zhong; Z Wen; J E Darnell
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

View more
  4 in total

Review 1.  Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

Authors:  Bharat B Aggarwal; Ajaikumar B Kunnumakkara; Kuzhuvelil B Harikumar; Shan R Gupta; Sheeja T Tharakan; Cemile Koca; Sanjit Dey; Bokyung Sung
Journal:  Ann N Y Acad Sci       Date:  2009-08       Impact factor: 5.691

2.  DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion.

Authors:  Elena A Tukhovskaya; Elvira R Shaykhutdinova; Alina M Ismailova; Gulsara A Slashcheva; Igor A Prudchenko; Inessa I Mikhaleva; Oksana N Khokhlova; Arkady N Murashev; Vadim T Ivanov
Journal:  Biomedicines       Date:  2021-04-09

3.  Commentary: One plus one does not always equal two: Mitochondrial cardioprotection.

Authors:  Alvise Guariento; Ilias Doulamis; Vladimiro Vida
Journal:  JTCVS Open       Date:  2021-08-20

4.  A Novel Biological Strategy for Myocardial Protection by Intracoronary Delivery of Mitochondria: Safety and Efficacy.

Authors:  Borami Shin; Mossab Y Saeed; Jesse J Esch; Alvise Guariento; David Blitzer; Kamila Moskowitzova; Giovanna Ramirez-Barbieri; Arzoo Orfany; Jerusha K Thedsanamoorthy; Douglas B Cowan; James A Inkster; Erin R Snay; Steven J Staffa; Alan B Packard; David Zurakowski; Pedro J Del Nido; James D McCully
Journal:  JACC Basic Transl Sci       Date:  2019-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.